ZGC TEC LEASING (01601) has entered into a partnership agreement for a fund with a registered capital of 415 million yuan.
Zhongguancun Technology Leasing (01601) announced that on August 20, 2026, the Group will enter into a partnership agreement with fund partners to establish and operate a fund with a registered capital of RMB 415 million (Beijing Zhongfa Zhongnuo Hu Yang Jichun Venture Capital Fund Partnership (Limited Partnership)), of which RMB 205.425 million is subscribed by the Company, accounting for 49.5% of the total committed capital of the fund. RMB 125 million is subscribed by Beijing Zhongnuo, accounting for 0.3% of the total committed capital of the fund.
ZGC TEC LEASING (01601) announced that on August 20, 2026, the Group entered into a partnership agreement with fund partners to establish and operate a fund with a registered capital of RMB 415 million (Beijing Zhongfa Zhongnuo Hu Yang Jichun Venture Capital Fund Partnership (Limited Partnership)), of which RMB 205.425 million is subscribed by our company, accounting for 49.5% of the total committed capital of the fund. Additionally, RMB 125 million is subscribed by Beijing Zhongnuo, accounting for 0.3% of the total committed capital of the fund.
The "integration of industry and finance business" is an important strategic path to enhance the company's competitive advantage. In order to further improve the company's competitive edge and to enhance our ability to acquire and service quality clients, the company is establishing a fund to, on one hand, meet the demand of our growing clients for equity financing products and optimize their financing structure, and on the other hand, identify potential clients for financing leasing through equity investment, creating a beneficial situation of mutual promotion and support between our leasing and investment operations.
The company's investment in the fund is utilizing the company's internal resources. The Board confirms that the investment will not affect the daily operations of the company's main business.
Related Articles

LUYE PHARMA (02186) is set to launch II phase clinical trials in China for its mRNA vaccine LY01620, intended for the treatment of cervical precancerous lesions and HPV-related tumors.

CHINA POWER (02380) achieved strong growth in its hydropower segment in the first half of the year, with clean energy installed capacity accounting for over 80%.

3SBIO (01530) released its mid-term results, with a net profit attributable to shareholders of 1.147 billion yuan, a decrease of 15.58% year-on-year.
LUYE PHARMA (02186) is set to launch II phase clinical trials in China for its mRNA vaccine LY01620, intended for the treatment of cervical precancerous lesions and HPV-related tumors.

CHINA POWER (02380) achieved strong growth in its hydropower segment in the first half of the year, with clean energy installed capacity accounting for over 80%.

3SBIO (01530) released its mid-term results, with a net profit attributable to shareholders of 1.147 billion yuan, a decrease of 15.58% year-on-year.

RECOMMEND





